General Information of Drug (ID: DM0RXF5)

Drug Name
Hyqvia Drug Info
Synonyms Immunoglobulin infusion with recombinant hyaluronidase
Indication
Disease Entry ICD 11 Status REF
Immunodeficiency 4A00-4A85 Approved [1]
Cross-matching ID
TTD Drug ID
DM0RXF5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Hyaluronidase (HYAL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Asenapine DMSQZE2 Schizophrenia 6A20 Approved [2]
PEGPH20 DM26YJ1 Non-small-cell lung cancer 2C25.Y Phase 2 [3]
PEGylated hyaluronidase (human recombinant) DM1D6BT Pancreatic cancer 2C10 Phase 1/2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hyaluronidase (HYAL) TTXFI1K NOUNIPROTAC Modulator [1]

References

1 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.